Key Takeaways: Vanguard will now allow trading of regulated crypto ETFs and mutual funds, including products backed by Bitcoin, Ether, XRP, and Solana. The move reverses decades of anti-crypto policy, The post Vanguard Opens the Door to Crypto ETFs, Unlocking Access for 50 million Investors appeared first on CryptoNinjas.Key Takeaways: Vanguard will now allow trading of regulated crypto ETFs and mutual funds, including products backed by Bitcoin, Ether, XRP, and Solana. The move reverses decades of anti-crypto policy, The post Vanguard Opens the Door to Crypto ETFs, Unlocking Access for 50 million Investors appeared first on CryptoNinjas.

Vanguard Opens the Door to Crypto ETFs, Unlocking Access for 50 million Investors

Key Takeaways:

  • Vanguard will now allow trading of regulated crypto ETFs and mutual funds, including products backed by Bitcoin, Ether, XRP, and Solana.
  • The move reverses decades of anti-crypto policy, giving more than 50 million Vanguard clients access to digital-asset investment vehicles.
  • The shift reflects rising demand and the maturity of crypto ETF infrastructure, which has grown into one of the fastest-expanding fund categories in U.S. history.

Vanguard’s stance on digital assets has long stood out as one of the most conservative in traditional finance. That changed this week as the world’s second-largest asset manager confirmed it will begin supporting crypto ETFs and crypto-focused mutual funds on its brokerage platform. The move signals a dramatic departure from its rigid, anti-crypto policy and underscores how deeply digital assets have penetrated mainstream finance.

Below is a detailed breakdown of the implications of this shift, why it matters for the broader market, and how it changes the landscape for investors.

Vanguard’s Crypto Reversal: What Exactly Is Changing

For years, Vanguard resisted pressure to integrate digital assets, even as competitors like BlackRock, Fidelity, Franklin Templeton, and Invesco aggressively expanded into crypto. Vanguard repeatedly argued that crypto was too volatile and lacked long-term investment merit.

That era is officially over.

Beginning Tuesday, Vanguard brokerage users will be allowed to trade ETFs and mutual funds that primarily hold regulated cryptocurrencies. Eligible assets include exposure to major networks such as:

  • Bitcoin (BTC)
  • Ethereum (ETH)
  • XRP
  • Solana (SOL)

The move gives investors access to regulated products such as spot Bitcoin ETFs, ETH ETFs, diversified digital-asset funds, and crypto basket products, all of which have attracted hundreds of billions in flows across U.S. markets since 2024.

This is not a small shift. Vanguard’s brokerage arm serves more than 50 million investors, many of whom have never had direct access to crypto exposure through the platform.

Read More: CoinShares Abruptly Withdraws Multiple SEC ETF Filings Ahead of $1.2B Nasdaq Listing Pivot

Why Vanguard Changed Its Stance

The shift in institutional finance is motivated by a number of factors that are transforming the firm:

  • Persistent user demand, even during market corrections
  • Record-breaking ETF growth, especially in Bitcoin ETFs, now the fastest-growing ETF category in U.S. history
  • Stabilization of crypto ETF infrastructure, which has proven resilient during volatility
  • Competitive pressure, as BlackRock and Fidelity dominate crypto inflows

Solo spot Bitcoin ETFs have passed over $120 billion AUM in 18 months, and certain funds such as the IBIT by BlackRock, has been rated as one of the best ETFs worldwide in terms of inflows.

With crypto ETF infrastructure now tested, liquid, and highly regulated, Vanguard no longer sees digital-asset funds as an operational or compliance risk.

A Major Turning Point for Traditional Finance

Crypto ETFs Have Become Too Large to Ignore

Crypto ETFs have outpaced the early growth of gold ETFs, fixed-income ETFs, and thematic funds. Even during market downturns, trading volumes have remained strong, and liquidity depth has improved across Bitcoin, Ether, and multi-asset crypto funds.

This consistency helped convince Vanguard leadership that digital assets, when wrapped in ETF and mutual fund structures, now meet the firm’s standards for:

  • Liquidity
  • Operational maturity
  • Regulatory oversight
  • Investor protection

Even the most conservative asset managers are now acknowledging that the crypto ETF market has “institutionalized.”

A Signal to the Rest of Wall Street

Vanguard’s reversal marks a psychological milestone. The most significant traditional finance establishment is finally opening its doors to digital assets, which is an indication that crypto is not a marginal asset category but is now a component of mainstream portfolio building.

Of particular significance to the decision is the fact that:

  • Vanguard manages approximately $11 trillion in client assets
  • The firm’s founder, John Bogle, famously warned investors to “avoid Bitcoin like the plague”
  • Vanguard historically positioned itself as the opposite of speculative investing

This adoption has seen close to all the largest asset managers in the United States such as BlackRock, Fidelity, State Street, Franklin Templeton, and WisdomTree all participate in crypto in one way.

Read More: Bitwise Confirms XRP ETF Launch Dates for Trading on NYSE in Major Crypto Milestone

What Vanguard Clients Can Expect

Access, but Not In-House Crypto Products

Vanguard will not launch its own Bitcoin or crypto ETF. Executives made that clear.

However, the firm will treat crypto ETFs the same way it treats gold ETFs and other non-core asset classes: accessible, regulated, and supported on its trading platform.

The company will continue to exclude:

  • Memecoin-linked funds
  • Unregulated products
  • Crypto vehicles lacking SEC approval

This ensures Vanguard remains aligned with its conservative risk framework while still expanding access.

The post Vanguard Opens the Door to Crypto ETFs, Unlocking Access for 50 million Investors appeared first on CryptoNinjas.

Market Opportunity
Nowchain Logo
Nowchain Price(NOW)
$0.00074
$0.00074$0.00074
-8.64%
USD
Nowchain (NOW) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26